Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R548
- Development stage
- Unknown
- Lead developer
- Rigel Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
R548 is an investigational small molecule drug developed by Rigel Pharmaceuticals. It is a selective Janus kinase 1 (JAK1) inhibitor designed for the treatment of autoimmune and inflammatory diseases. The mechanism of action involves inhibition of JAK1, a key enzyme in the signaling pathways for various cytokines involved in immune response and inflammation. By selectively targeting JAK1, R548 aims to modulate immune activity with potentially fewer side effects compared to less selective JAK inhibitors. As of current knowledge, it has been studied primarily for rheumatoid arthritis and other autoimmune conditions.
02
Targets
Beyond the preview
Go deeper on R548.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R548.